home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2801.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
37 lines
Document 2801
DOCN M94A2801
TI Treatment with thalidomide in AIDS patients.
DT 9412
AU Klausner JD; Makonkawkeyoon S; Akarasewi P; Kasinrerk W; Nakata K;
Kaplan G; NYU Med Cntr. Dept of Med., NY.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):221 (abstract no. PB0312). Unique
Identifier : AIDSLINE ICA10/94369774
AB OBJECTIVES: To demonstrate that thalidomide reduces the toxic
manifestations of tumor necrosis factor (TNF) and decreases HIV-1 viral
burden in patients with AIDS. METHODS: In a randomized, double-blind,
prospective study, 41 male patients with AIDS and 6 months of weight
loss were given 300 mg of thalidomide or placebo nightly for 21 days.
Baseline and serial weekly symptom scores, body weights, CD 4 counts and
plasma for HIV-1 titers were obtained. RESULTS: Treated patients (n =
16, mean age 32, 48% with tuberculosis (TB), median CD4 count = 34)
reported an increased appetite and gained an average of 4.5% in body
weight versus 0.9% (P < 0.01) in controls (n = 16, mean age 32, 45% with
TB, median CD4 count = 36). Six (29%) patients on thalidomide developed
a drug rash. CD4 counts did not change with therapy. P24 antigen titers
were measurable in 5 patients and decreased in 3 patients on
thalidomide. DISCUSSION AND CONCLUSIONS: Thalidomide increased appetite
and produced weight gain in AIDS patients with wasting. There was no
significant adverse effect on immunosuppression and its effect on HIV-1
viral burden is forthcoming.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG THERAPY/
MICROBIOLOGY Adult Appetite/DRUG EFFECTS Double-Blind Method Human
HIV-1/ISOLATION & PURIF Male Prospective Studies
Thalidomide/PHARMACOLOGY/*THERAPEUTIC USE Treatment Outcome
Tuberculosis/COMPLICATIONS Tumor Necrosis Factor/*ANALYSIS Weight
Gain/DRUG EFFECTS CLINICAL TRIAL MEETING ABSTRACT RANDOMIZED
CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).